Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership with Fudan University Shanghai Cancer Center. The RMB 31 million (USD 4.5 million) deal will see the two Chinese entities collaborate on the translation of “breast cancer multi-gene detection” technology, marking a significant step forward in the field of oncology.
Breast Cancer Multi-Gene Detection Technology
The “breast cancer multi-gene detection” scheme proposed by Fudan Cancer Center is based on the self-developed design of a large breast cancer cohort of Chinese patients. This program, which has completely independent intellectual property rights (including three patents and two software copyrights), has been unanimously recognized by scientific and industrial circles in China and overseas. It covers high-frequency variant genes, genetic susceptibility genes, genes related to targeted drug guidance, and drug-resistant genes within the Chinese breast cancer population.
Topgen Biopharm’s Research and Development
Founded in 2012, Topgen Biopharm boasts a research and development center in Shanghai and a nationwide laboratory network. This partnership with Fudan University Shanghai Cancer Center will further enhance Topgen’s capabilities in precision medicine, particularly in the area of breast cancer research and treatment. The collaboration is expected to accelerate the development and application of multi-gene detection technology, improving the diagnosis and treatment of breast cancer in China.-Fineline Info & Tech
